Evidence map›Paper›PMID 35795769›Full record

ArticleComputational intelligence and neuroscience2022

Comparison of Efficacy and Safety of TACE Combined with Microwave Ablation and TACE Combined with Cryoablation in the Treatment of Large Hepatocellular Carcinoma.

Yujia Wang, Wei Li, Wenling Man, Xiaolin Dong, Yinghao Luo, Yan Zhang, Yongchuang Zhang, Chang Dong, Weiwei Sun, Po Yang

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Computational intelligence and neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yujia WangThe Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Wei LiThe Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Wenling ManThe Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Xiaolin DongThe Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Yinghao LuoThe Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Yan ZhangThe Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Yongchuang ZhangThe Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Chang DongThe Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Weiwei SunThe Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Po YangThe Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.ORCID https://orcid.org/0000-0002-9378-4005
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To retrospectively evaluate the efficacy and safety of TACE combined with microwave ablation (MWA) and TACE combined with cryoablation (CRA) in the treatment of large hepatocellular carcinoma. Methods: A retrospective analysis was performed on 81 patients with large hepatocellular carcinoma (tumor diameter 5~8 cm cm) who received TACE combined with ablation in our hospital from February 2015 to February 2019. The study patients were divided into TACE combined with MWA group (T-MWA, Results: There was no statistical difference in general conditions between the two groups of patients. The results showed that 30 (73.2%) patients in T-MWA group achieved objective response (OR) and 39 (95.1%) patients achieved disease control (DC), compared with 24 (60.0%) patients in T-CRA group who achieved objective response (OR) and 37 (92.5%) patients who achieved disease control (DC). The median OS was 19.2 months in the T-MWA group and 18.6 months in the T-CRA group ( Conclusion: TACE combined with MWA and TACE combined with CRA were equally effective in the treatment of large hepatocellular carcinoma. TACE-CRA can effectively reduce the incidence of abdominal pain and gastrointestinal reactions in patients. However, compared with TACE-MWA, TACE-CRA is more likely to cause thrombocytopenia.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticCryosurgeryLiver NeoplasmsAbdominal PainHumansMicrowavesRetrospective StudiesTreatment Outcome

Identifiers

PMID35795769
PMCPMC9252684
OpenAlexW4283526503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.